Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5642_Библиотеки_им_академика_М_И_Перельмана
.pdf
22.
Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary clearance, vol. 9.
Cold Spring Harb Perspect Biol; 2017.
23.
Carvalho TC, McConville JT. The function and performance of aqueous aerosol
devices for inhalation therapy. J Pharm Pharmacol. 2016;68:556–78.
[PubMed]
24.
Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to
therapeutic application. Clin Exp Pharmacol Physiol. 2006;33:533–40.
[PubMed]
25.
Chang RYK, Chan HK. Lipid nanoparticles for the inhalation of mRNA. Nat
Biomed Eng. 2021;5:949–50.
[PubMed]
26.
Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ
targeting (SORT) nanoparticles for tissue-speciic mRNA delivery and CRISPRCas gene editing. Nat Nanotechnol. 2020;15:313–20.
[PubMed][PubMedCentral]
27.
Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical
applications. Postdoc J. 2016;4:35–50.
[PubMed][PubMedCentral]
28.
Chow MYT, Chang RYK, Chan HK. Inhalation delivery technology for genomeediting of respiratory diseases. Adv Drug Deliv Rev. 2021;168:217–28.
[PubMed]
29.
Chow MYT, Qiu Y, Lam JKW. Inhaled RNA therapy: from promise to reality.
Trends Pharmacol Sci. 2020;41:715–29.
[PubMed][PubMedCentral]
30.
ClinicalTrials.gov (a). Eficacy and safety of four escalating dose regimens of
TPI ASM8 in patients with allergic asthma. Accessed 23/02/2023. https:// beta.
clinicaltrials. gov/ study/ NCT00822861
31.
ClinicalTrials.gov (b). Safety, eficacy, PK, and PD characteristics of orally
inhaled SB010 in male patients with mild asthma (multiple dose). Accessed
23/02/2023. https:// beta. clinicaltrials. gov/ study/ NCT01743768
32.
ClinicalTrials.gov (c). Study evaluating the effects of AIR645 on allergeninduced airway responses in subjects with mild atopic asthma. Accessed
23/02/2023. https:// beta. clinicaltrials. gov/ study/ NCT00941577
https://t.me/medicina_free
33.
ClinicalTrials.gov (d). Eficacy, safety, and tolerability of remlarsen (MRG-201)
following intradermal injection in subjects with a history of keloids. Accessed
23/02/2023. https:// beta. clinicaltrials. gov/ study/ NCT03601052
34.
ClinicalTrials.gov (e). Intranasal ALN-RSV01 administered to adult volunteers
experimentally inoculated with respiratory syncytial virus. Accessed
23/02/2023. https:// beta. clinicaltrials. gov/ study/ NCT00496821
35.
ClinicalTrials.gov (f). Phase 2b study of ALN-RSV01 in lung transplant patients
infected with respiratory syncytial virus (RSV). Accessed 23/02/2023. https://
beta. clinicaltrials. gov/ study/ NCT01065935
36.
ClinicalTrials.gov (g). Safety, tolerability, and pharmacokinetic study of TRK250 for patients with idiopathic pulmonary ibrosis. Accessed 23/02/2023.
https:// beta. clinicaltrials. gov/ study/ NCT03727802
37.
Colombo S, Cun D, Remaut K, Bunker M, Zhang J, Martin-Bertelsen B, Yaghmur
A, Braeckmans K, Nielsen HM, Foged C. Mechanistic proiling of the siRNA
delivery dynamics of lipid-polymer hybrid nanoparticles. J Control Release.
2015;201:22–31.
[PubMed]
38.
Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61:75–85.
[PubMed]
39.
Conte G, Costabile G, Baldassi D, Rondelli V, Bassi R, Colombo D, Linardos G,
Fiscarelli EV, Sorrentino R, Miro A. Hybrid lipid/polymer nanoparticles to
tackle the cystic ibrosis mucus barrier in siRNA delivery to the lungs: does
PEGylation make the difference? ACS Appl Mater Interfaces. 2022;14:7565–78.
[PubMed][PubMedCentral]
40.
Costa B, Boueri B, Oliveira C, Silveira I, Ribeiro AJ. Lipoplexes and polyplexes as
nucleic acids delivery nanosystems: the current state and future
considerations. Expert Opin Drug Deliv. 2022;19:577–94.
[PubMed]
41.
Cryan S-A, Sivadas N, Garcia-Contreras L. In vivo animal models for drug
delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007;59:1133–51.
[PubMed]
42.
d’Angelo I, Costabile G, Durantie E, Brocca P, Rondelli V, Russo A, Russo G, Miro
A, Quaglia F, Petri-Fink A, Rothen-Rutishauser B, Ungaro F. Hybrid
lipid/polymer nanoparticles for pulmonary delivery of siRNA: development
https://t.me/medicina_free
and fate upon in vitro deposition on the human epithelial airway barrier. J
Aerosol Med Pulm Drug Deliv. 2018;31:170–81.
[PubMed]
43.
de Groot AM, Thanki K, Gangloff M, Falkenberg E, Zeng X, van Bijnen DCJ, van
Eden W, Franzyk H, Nielsen HM, Broere F, Gay NJ, Foged C, Sijts A.
Immunogenicity testing of lipidoids in vitro and in silico: modulating lipidoidmediated TLR4 activation by nanoparticle design. Mol Ther Nucleic Acids.
2018;11:159–69.
[PubMed][PubMedCentral]
44.
Degors IMS, Wang C, Rehman ZU, Zuhorn IS. Carriers break barriers in drug
delivery: endocytosis and endosomal escape of gene delivery vectors. Acc
Chem Res. 2019;52:1750–60.
[PubMed][PubMedCentral]
45.
Ding L, Tang S, Wyatt TA, Knoell DL, Oupicky D. Pulmonary siRNA delivery for
lung disease: review of recent progress and challenges. J Control Release.
2021;330:977–91.
[PubMed]
46.
Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, Qin Z, Xu Z, Sun W, Liang Y.
Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front Genet.
2021;12:673286.
[PubMed][PubMedCentral]
47.
Faria J, Magalhaes M, Veiga F, Santos AC, Figueiras A. Micelleplexes: A promising
nanocarrier for the transport of genetic material and drugs. In: Patra JK, Shukla
AC, Das G, editors. Advances in pharmaceutical biotechnology: recent progress
and future applications. Springer: Singapore; 2020.
48.
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano.
2009;3:16–20.
[PubMed]
49.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and
speciic genetic interference by double-stranded RNA in Caenorhabditis
elegans. Nature. 1998;391:806–11.
[PubMed]
50.
Fluiter K, Mook ORF, Baas F. The therapeutic potential of LNA-modiied siRNAs:
reduction of off-target effects by chemical modiication of the siRNA sequence.
siRNA miRNA Gene Silenc. 2009:1–15.
https://t.me/medicina_free
51.
Garcia-Mouton C, Hidalgo A, Cruz A, Perez-Gil J. The lord of the lungs: the
essential role of pulmonary surfactant upon inhalation of nanoparticles. Eur J
Pharm Biopharm. 2019;144:230–43.
[PubMed]
52.
Gauvreau GM, Pageau R, Seguin R, Carballo D, Gauthier J, D’Anjou H, Campbell H,
Watson R, Mistry M, Parry-Billings M, Killian K, Renzi PM. Dose-response
effects of TPI ASM8 in asthmatics after allergen. Allergy. 2011;66:1242–8.
[PubMed]
53.
Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U,
Manygoats K, Seifert S, Andree C, Stoter M, Epstein-Barash H, Zhang L,
Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M,
Zerial M. Image-based analysis of lipid nanoparticle-mediated siRNA delivery,
intracellular traficking and endosomal escape. Nat Biotechnol. 2013;31:638–
46.
[PubMed]
54.
Goodwin EC, Rottman FM. The 3′-lanking sequence of the bovine growth
hormone gene contains novel elements required for eficient and accurate
polyadenylation. J Biol Chem. 1992;267:16330–4.
[PubMed]
55.
Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, Lienenklaus S,
Schultze A, Hasenpusch G, Garrels W, Stanke F, Miskey C, Johler SM, Kumar Y,
Tummler B, Rudolph C, Ivics Z, Rosenecker J. Self-assembled peptidepoloxamine nanoparticles enable in vitro and in vivo genome restoration for
cystic ibrosis. Nat Nanotechnol. 2019;14:287–97.
[PubMed]
56.
Gunther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines
for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J
Pharm Biopharm. 2011:1.
57.
Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic
applications. Adv Drug Deliv Rev. 2021;178:113834.
[PubMed]
58.
Hall TMT. Multiple modes of RNA recognition by zinc inger proteins. Curr Opin
Struct Biol. 2005;15:367–73.
[PubMed]
https://t.me/medicina_free
59.
Hastedt JE, Ba ckman P, Clark AR, Doub W, Hickey A, Hochhaus G, Kuehl PJ, Lehr
C-M, Mauser P, McConville J. Scope and relevance of a pulmonary
biopharmaceutical classiication system AAPS/FDA/USP workshop, March 16–
17th, 2015 in Baltimore, MD. Springer; 2016.
60.
Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat
Rev Mater. 2021:1–17.
61.
Huckaby JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus.
Adv Drug Deliv Rev. 2018;124:125–39.
[PubMed]
62.
Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30:3481–500.
[PubMed][PubMedCentral]
63.
Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-speciic context.
Nat Rev Immunol. 2014;14:81–93.
[PubMed]
64.
Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme
complex. Science. 2002;297:2056–60.
[PubMed]
65.
Ibrahim BM, Tsifansky MD, Yang Y, Yeo Y. Challenges and advances in the
development of inhalable drug formulations for cystic ibrosis lung disease.
Expert Opin Drug Deliv. 2011;8:451–66.
[PubMed]
66.
Ihara D, Hattori N, Horimasu Y, Masuda T, Nakashima T, Senoo T, Iwamoto H,
Fujitaka K, Okamoto H, Kohno N. Histological quantiication of gene silencing
by intratracheal administration of dry powdered small-interfering
RNA/chitosan complexes in the murine Lung. Pharm Res. 2015;32:3877–85.
[PubMed]
67.
Imaoka H, Campbell H, Babirad I, Watson RM, Mistry M, Sehmi R, Gauvreau GM.
TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge.
Clin Exp Allergy. 2011;41:1740–6.
[PubMed]
68.
Ito T, Fukuhara M, Okuda T, Okamoto H. Naked pDNA/hyaluronic acid powder
shows excellent long-term storage stability and gene expression in murine
lungs. Int J Pharm. 2020;574:118880.
[PubMed]
https://t.me/medicina_free
69.
Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G,
Linsley PS. Expression proiling reveals off-target gene regulation by RNAi. Nat
Biotechnol. 2003;21:635–7.
[PubMed]
70.
Jain KK. Role of nanobiotechnology in drug delivery. Drug Deliv Syst. 2020:55–
73.
71.
Jansen EM, Frijlink HW, Hinrichs WL, Ruigrok MJ. Are inhaled mRNA vaccines
safe and effective? A review of preclinical studies. Expert Opin Drug Deliv.
2022;19:1471–85.
[PubMed]
72.
Jia Y, Krishnan L, Omri A. Nasal and pulmonary vaccine delivery using
particulate carriers. Expert Opin Drug Deliv. 2015;12:993–1008.
[PubMed]
73.
Jiang Y, Fan M, Yang Z, Liu X, Xu Z, Liu S, Feng G, Tang S, Li Z, Zhang Y, Chen S,
Yang C, Law WC, Dong B, Xu G, Yong KT. Recent advances in nanotechnology
approaches for non-viral gene therapy. Biomater Sci. 2022:1.
74.
Johnson MD, Widdicombe JH, Allen L, Barbry P, Dobbs LG. Alveolar epithelial
type I cells contain transport proteins and transport sodium, supporting an
active role for type I cells in regulation of lung liquid homeostasis. Proc Natl
Acad Sci. 2002;99:1966–71.
[PubMed][PubMedCentral]
75.
Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting
station for proteins at the crossroads. Histol Histopathol. 2010;25:99–112.
[PubMed][PubMedCentral]
76.
Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA
therapeutics: from concept to clinical reality. Genome Med. 2017;9:1–16.
77.
Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D.
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic
vector with increased translational capacity and biological stability. Mol Ther.
2008;16:1833–40.
[PubMed]
78.
Ke X, Shelton L, Hu Y, Zhu Y, Chow E, Tang H, Santos JL, Mao HQ. Surfacefunctionalized PEGylated nanoparticles deliver messenger RNA to pulmonary
immune cells. ACS Appl Mater Interfaces. 2020;12:35835–44.
https://t.me/medicina_free
[PubMed][PubMedCentral]
79.
Keil TWM, Baldassi D, Merkel OM. T-cell targeted pulmonary siRNA delivery
for the treatment of asthma. Wiley Interdiscip Rev Nanomed Nanobiotechnol.
2020;12:e1634.
[PubMed][PubMedCentral]
80.
Keil TWM, Feldmann DP, Costabile G, Zhong Q, da Rocha S, Merkel OM.
Characterization of spray dried powders with nucleic acid-containing PEI
nanoparticles. Eur J Pharm Biopharm. 2019;143:61–9.
[PubMed][PubMedCentral]
81.
Keil TW, Zimmermann CM, Baldassi D, Adams F, Friess W, Mehta A, Merkel OM.
Impact of crystalline and amorphous matrices on successful spray drying of
siRNA polyplexes for inhalation of nano-in-microparticles. Adv Ther. 2021:1.
82.
Kim J, Jozic A, Lin Y, Eygeris Y, Bloom E, Tan X, Acosta C, MacDonald KD,
Welsher KD, Sahay G. Engineering lipid nanoparticles for enhanced intracellular
delivery of mRNA through inhalation. ACS Nano. 2022;16:14792–806.
[PubMed][PubMedCentral]
83.
Knoch M, Keller M. The customised electronic nebuliser: a new category of
liquid aerosol drug delivery systems. Expert Opin Drug Deliv. 2005;2:377–90.
[PubMed]
84.
Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and
antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125–40.
[PubMed][PubMedCentral]
85.
Kolte A, Patil S, Lesimple P, Hanrahan JW, Misra A. PEGylated composite
nanoparticles of PLGA and polyethylenimine for safe and eficient delivery of
pDNA to lungs. Int J Pharm. 2017;524:382–96.
[PubMed]
86.
Krohn-Grimberghe M, Mitchell MJ, Schloss MJ, Khan OF, Courties G, Guimaraes
PPG, Rohde D, Cremer S, Kowalski PS, Sun Y, Tan M, Webster J, Wang K,
Iwamoto Y, Schmidt SP, Wojtkiewicz GR, Nayar R, Frodermann V, Hulsmans M,
Chung A, Hoyer FF, Swirski FK, Langer R, Anderson DG, Nahrendorf M.
Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic
stem-cell niche. Nat Biomed Eng. 2020;4:1076–89.
[PubMed][PubMedCentral]
87.
Kumar US, Ajei R, Ferrara K, Massoud TF, Paulmurugan R. Gold-nanostarchitosan-mediated delivery of SARS-CoV-2 DNA vaccine for respiratory
https://t.me/medicina_free
mucosal immunization: development and proof-of-principle. ACS Nano. 2021:1.
88.
Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics
for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
[PubMed][PubMedCentral]
89.
Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before
prescribing inhaled medications: a pragmatic approach for evaluating the
current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532.
[PubMed][PubMedCentral]
90.
Leng D, Thanki K, Fattal E, Foged C, Yang M. Engineering of budesonide-loaded
lipid-polymer hybrid nanoparticles using a quality-by-design approach. Int J
Pharm. 2018;548:740–6.
[PubMed]
91.
Leonova EI, Gainetdinov RR. CRISPR/Cas9 technology in translational
biomedicine. Cell Physiol Biochem. 2020;54:354–70.
[PubMed]
92.
Levine-Tiefenbrun M, Yelin I, Alapi H, Herzel E, Kuint J, Chodick G, Gazit S,
Patalon T, Kishony R. Waning of SARS-CoV-2 booster viral-load reduction
effectiveness. Nat Commun. 2022;13:1237.
[PubMed][PubMedCentral]
93.
Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human
genome engineering by controlled timing of CRISPR/Cas9 delivery. elife.
2014;3:e04766.
[PubMed][PubMedCentral]
94.
Liu Q, Guan J, Song R, Zhang X, Mao S. Physicochemical properties of
nanoparticles affecting their fate and the physiological function of pulmonary
surfactants. Acta Biomater. 2022;140:76–87.
[PubMed]
95.
Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES,
Peck HE, Ni H, Yoon J-K, Kim YT. Optimization of lipid nanoparticles for the
delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng.
2021;5:1059–68.
[PubMed][PubMedCentral]
96.
Marczynski M, Jiang K, Blakeley M, Srivastava V, Vilaplana F, Crouzier T, Lieleg
O. Structural alterations of mucins are associated with losses in functionality.
Biomacromolecules. 2021;22:1600–13.
https://t.me/medicina_free
[PubMed]
97.
Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin
Drug Deliv. 2015;12:889–900.
[PubMed]
98.
McLachlan G, Alton EWFW, Boyd AC, Clarke NK, Davies JC, Gill DR, Griesenbach
U, Hickmott JW, Hyde SC, Miah KM, Molina CJ. Progress in respiratory gene
therapy. Hum Gene Ther. 2022;33:893–912.
[PubMed]
99.
Merkel OM, Kissel T. Nonviral pulmonary delivery of siRNA. Acc Chem Res.
2012;45:961–70.
[PubMed]
100.
Merkel OM, Beyerle A, Librizzi D, Pfestroff A, Behr TM, Sproat B, Barth PJ, Kissel
T. Nonviral siRNA delivery to the lung: investigation of PEG-PEI Polyplexes and
their in vivo performance. Mol Pharm. 2009;6:1246–60.
[PubMed]
101.
Mohamed A, Pekoz AY, Ross K, Hutcheon GA, Saleem IY. Pulmonary delivery of
nanocomposite microparticles (NCMPs) incorporating miR-146a for treatment
of COPD. Int J Pharm. 2019;569:118524.
[PubMed]
102.
Mohwald M, Pinnapireddy SR, Wonnenberg B, Pourasghar M, Jurisic M, Jung A,
Fink-Straube C, Tschernig T, Bakowsky U, Schneider M. Aspherical,
nanostructured microparticles for targeted gene delivery to alveolar
macrophages. Adv Healthc Mater. 2017:6.
103.
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipidpolymer hybrid nanoparticles as a next-generation drug delivery platform:
state of the art, emerging technologies, and perspectives. Int J Nanomedicine.
2019;14:1937–52.
[PubMed][PubMedCentral]
104.
Munir M, Kett VL, Dunne NJ, McCarthy HO. Development of a spray-dried
formulation of peptide-DNA nanoparticles into a dry powder for pulmonary
delivery using factorial design. Pharm Res. 2022;39:1215–32.
[PubMed][PubMedCentral]
105.
Murgia X, Loretz B, Hartwig O, Hittinger M, Lehr C-M. The role of mucus on
drug transport and its potential to affect therapeutic outcomes. Adv Drug Deliv
Rev. 2018;124:82–97.
https://t.me/medicina_free
[PubMed]
106.
Nemati E, Mokhtarzadeh A, Panahi-Azar V, Mohammadi A, Hamishehkar H,
Mesgari-Abbasi M, Dolatabadi JEN, de la Guardia M. Ethambutol-loaded solid
lipid nanoparticles as dry powder inhalable formulation for tuberculosis
therapy. AAPS PharmSciTech. 2019;20:1–9.
107.
Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther
Deliv. 2017;8:647–61.
[PubMed]
108.
Ng B, Cash-Mason T, Wang Y, Seitzer J, Burchard J, Brown D, Dudkin V, Davide J,
Jadhav V, Sepp-Lorenzino L. Intratracheal administration of siRNA triggers
mRNA silencing in the lung to modulate T cell immune response and lung
Inlammation. Mol Ther Nucleic Acids. 2019;16:194–205.
[PubMed][PubMedCentral]
109.
Nguyen J, Steele TWJ, Merkel O, Reul R, Kissel T. Fast degrading polyesters as
siRNA nano-carriers for pulmonary gene therapy. J Control Release.
2008;132:243–51.
[PubMed][PubMedCentral]
110.
Nimesh S, Chandra R, Gupta N. Advances in nanomedicine for the delivery of
therapeutic nucleic acids. Woodhead Publishing; 2017.
111.
Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon-beta
gene complex powder for inhalation treatment of lung metastasis in mice. J
Control Release. 2011;150:187–95.
[PubMed]
112.
Okuda T, Morishita M, Mizutani K, Shibayama A, Okazaki M, Okamoto H.
Development of spray-freeze-dried siRNA/PEI powder for inhalation with high
aerosol performance and strong pulmonary gene silencing activity. J Control
Release. 2018;279:99–113.
[PubMed]
113.
Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD,
Hope MJ, Weissman D. Expression kinetics of nucleoside-modiied mRNA
delivered in lipid nanoparticles to mice by various routes. J Control Release.
2015;217:345–51.
[PubMed][PubMedCentral]
114.
Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, Uhler T,
Tuyishime S, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D, Muzykantov
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана